Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group.

Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Jones J, Kozuch PL, Melmed GY, Velayos FS, Siegel CA.

Gastroenterol Hepatol (N Y). 2008 Oct;4(10):713-20.

PMID:
21960891
[PubMed]
Free PMC Article
2.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
[PubMed - indexed for MEDLINE]
3.

Maintenance of remission in Crohn's disease: current and emerging therapeutic options.

Brookes MJ, Green JR.

Drugs. 2004;64(10):1069-89. Review.

PMID:
15139787
[PubMed - indexed for MEDLINE]
4.

Antibiotics as primary therapy for Crohn's disease.

Chamberlin W, Hulten K, Graham DY.

Drugs Today (Barc). 2000 Oct;36(10):667-78.

PMID:
12847571
[PubMed]
5.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA.

Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6.

PMID:
20451665
[PubMed - indexed for MEDLINE]
6.

Current and future role of biomarkers in Crohn's disease risk assessment and treatment.

Tamboli CP, Doman DB, Patel A.

Clin Exp Gastroenterol. 2011;4:127-40. doi: 10.2147/CEG.S18187. Epub 2011 Jun 2.

PMID:
21753895
[PubMed]
Free PMC Article
7.

Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.

Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA.

Inflamm Bowel Dis. 2012 Dec;18(12):2294-300. doi: 10.1002/ibd.22920. Epub 2012 Feb 15.

PMID:
22337359
[PubMed - indexed for MEDLINE]
8.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
[PubMed - indexed for MEDLINE]
9.

Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.

Bourreille A, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, Bouhnik Y, Seidman E, Keuchel M, Albert JG, Ardizzone S, Bar-Meir S, Bisschops R, Despott EJ, Fortun PF, Heuschkel R, Kammermeier J, Leighton JA, Mantzaris GJ, Moussata D, Lo S, Paulsen V, Panés J, Radford-Smith G, Reinisch W, Rondonotti E, Sanders DS, Swoger JM, Yamamoto H, Travis S, Colombel JF, Van Gossum A; World Organisation of Digestive Endoscopy (OMED) and the European Crohn's and Colitis Organisation (ECCO).

Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. Review.

PMID:
19588292
[PubMed - indexed for MEDLINE]
10.

Current therapeutic approaches in inflammatory bowel disease.

Sohrabpour AA, Malekzadeh R, Keshavarzian A.

Curr Pharm Des. 2010;16(33):3668-83.

PMID:
21128898
[PubMed - indexed for MEDLINE]
11.

Mild to moderate Crohn's disease: still room for step-up therapies?

Bar-Meir S.

Dig Dis. 2009;27(3):347-50. doi: 10.1159/000228572. Epub 2009 Sep 24. Review.

PMID:
19786763
[PubMed - indexed for MEDLINE]
12.

A national survey on the patterns of treatment of inflammatory bowel disease in Canada.

Hilsden RJ, Verhoef MJ, Best A, Pocobelli G.

BMC Gastroenterol. 2003 Jun 5;3:10.

PMID:
12791168
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].

Ochsenkühn T, Sackmann M, Göke B.

Radiologe. 2003 Jan;43(1):1-8. Review. German.

PMID:
12552369
[PubMed - indexed for MEDLINE]
14.

Measles vaccination and inflammatory bowel disease: controversy laid to rest?

Davis RL, Bohlke K.

Drug Saf. 2001;24(13):939-46. Review.

PMID:
11735650
[PubMed - indexed for MEDLINE]
15.

Paediatric inflammatory bowel disease in New Zealand.

Yap J, Wesley A, Mouat S, Chin S.

N Z Med J. 2008 Oct 3;121(1283):19-34.

PMID:
18841182
[PubMed - indexed for MEDLINE]
16.

Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Hanauer SB, Stathopoulos G.

Drug Saf. 1991 May-Jun;6(3):192-219. Review.

PMID:
1676590
[PubMed - indexed for MEDLINE]
17.

Medical therapy for Crohn's disease: top-down or step-up?

Baert F, Caprilli R, Angelucci E.

Dig Dis. 2007;25(3):260-6.

PMID:
17827952
[PubMed - indexed for MEDLINE]
18.

Biologic therapy for inflammatory bowel disease.

Ardizzone S, Bianchi Porro G.

Drugs. 2005;65(16):2253-86. Review.

PMID:
16266194
[PubMed - indexed for MEDLINE]
19.

Skeletal morbidity in inflammatory bowel disease.

van Hogezand RA, Hamdy NA.

Scand J Gastroenterol Suppl. 2006;(243):59-64. Review.

PMID:
16782623
[PubMed - indexed for MEDLINE]
20.

Optimizing therapy for inflammatory bowel disease.

Robinson M.

Am J Gastroenterol. 1997 Dec;92(12 Suppl):12S-17S. Review.

PMID:
9395347
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk